0.00Open0.00Pre Close0 Volume0 Open Interest15.00Strike Price0.00Turnover584.76%IV-32.74%PremiumJul 26, 2024Expiry Date3.70Intrinsic Value100Multiplier1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.7141Delta0.0798Gamma2.60Leverage Ratio-0.4972Theta-0.0005Rho-1.85Eff Leverage0.0025Vega
Inovio Pharmaceuticals Stock Discussion
• BLA submission on track for INO-3107 in second half of 2024; if approved under accelerated approval pathway, could be first non-surgicaltreatment for recurrent respiratory papillomatosis (RRP)
• Planning initiation of confirmatory trial for INO-3107 based on FDA feedback
• Advancing plans for Phase 3 trial of INO-3112 in combination with LOQTORZITM ...
No comment yet